Finally, given the frequent co-occurrence of TP53 mutations and EGFR amplification in different tumor types, our findings suggest that targeting TAD- and DBD-specific modulation of EGFR activity could circumvent current challenges in directly targeting p53, or overcome resistance to EGFR inhibitors. Here, EGFR is linked to neoplasm.